- Trial phase
- Approved and marketed
- Time to market
- Already marketed. Launched in Japan in February 2015. US launch via Phathom as Voquezna in late 2023. Korean launch with insurance coverage begins November 1, 2026.
- Why 4/10
- Vonoprazan is already approved and marketed across multiple regions with no pending US/EU regulatory decision for Takeda (US rights are licensed to Phathom). The next dated catalyst is the Korean insurance reimbursement launch on November 1, 2026, a commercial event rather than a binary regulatory decision. As a ~3% contributor to a broadly diversified ¥4.5 trillion pharma company, a commercial launch in one country will not be a standalone share-price mover for TAK.
The next near-term event for the drug is the Korean national insurance reimbursement launch on November 1, 2026, announced today. This is a commercial expansion into a competitive market already dominated by three Korean-developed P-CABs (K-CAB, Fexuclue, Jaqbo). For a diversified pharma like Takeda, the stock move from vonoprazan-specific news is likely to be small; watch Phathom Pharmaceuticals (PHAT) for US Voquezna sales trajectory and the Phase 2 EoE readout expected late 2026/early 2027 instead.
Price Chart
Executive Summary
Vonoprazan (sold as TAKECAB in Japan, VOCINTI in other Asian markets, Voquezna in the US) is a first-in-class potassium-competitive acid blocker (P-CAB) discovered by Takeda. First approved in Japan in 2014, it is now marketed across Asia and Latin America by Takeda and in the US/Europe by partner Phathom Pharmaceuticals. The drug generated JPY 143.7 billion (~$950M) in sales for Takeda in FY2025 (up 9.9%), driven by Japan and China. Today (October 29, 2026), Takeda announced Korean insurance coverage for Vocinti starting November 1, entering a competitive market against established Korean P-CABs. Vonoprazan is an important growth product within Takeda's portfolio but represents roughly 3% of total company revenue. For Takeda investors, this is a steady commercial franchise with no imminent binary regulatory catalyst.
How It Works
Vonoprazan is a potassium-competitive acid blocker (P-CAB), a class of stomach-acid reducer that works by blocking the proton pump (the final step of acid production) in stomach-lining cells. Unlike standard proton-pump inhibitors (PPIs) that take days to reach full effect, P-CABs start working within hours and provide more consistent acid suppression regardless of when food is taken. It is taken as a once-daily tablet to treat acid reflux, erosive esophagitis, gastric ulcers, and H. pylori infection.
Trial Status
Vonoprazan is already approved in over 30 countries for acid-related diseases. Phathom is running a Phase 2 trial (pHalcon-EoE-201) in eosinophilic esophagitis with topline results expected late 2026 or early 2027, but this is a Phathom (PHAT) program, not a Takeda program. No late-stage pivotal trials remain for Takeda's own indications.
The Two-Sided Case
Upcoming Catalysts
- Korean national insurance reimbursement launch for Vocinti on November 1, 2026
- Potential generic competition as substance patent nears expiry in 2027
- Phathom's Phase 2 EoE readout (late 2026/early 2027) could indirectly support the drug class
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report